Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 22

1.

Development of Sanofi Pasteur tetravalent dengue vaccine.

Guy B, Saville M, Lang J.

Hum Vaccin. 2010 Sep 16;6(9). doi: 10.4161.hv.6.9.12739. Epub 2010 Sep 16.

PMID:
20861669
2.

From research to phase III: preclinical, industrial and clinical development of the Sanofi Pasteur tetravalent dengue vaccine.

Guy B, Barrere B, Malinowski C, Saville M, Teyssou R, Lang J.

Vaccine. 2011 Sep 23;29(42):7229-41. doi: 10.1016/j.vaccine.2011.06.094. Epub 2011 Jul 13. Review.

PMID:
21745521
3.

Development of the Sanofi Pasteur tetravalent dengue vaccine: One more step forward.

Guy B, Briand O, Lang J, Saville M, Jackson N.

Vaccine. 2015 Dec 10;33(50):7100-11. doi: 10.1016/j.vaccine.2015.09.108. Epub 2015 Oct 20. Review.

4.

Preclinical and clinical development of YFV 17D-based chimeric vaccines against dengue, West Nile and Japanese encephalitis viruses.

Guy B, Guirakhoo F, Barban V, Higgs S, Monath TP, Lang J.

Vaccine. 2010 Jan 8;28(3):632-49. doi: 10.1016/j.vaccine.2009.09.098. Epub 2009 Oct 4. Review.

PMID:
19808029
5.

Review of dengue virus and the development of a vaccine.

Murrell S, Wu SC, Butler M.

Biotechnol Adv. 2011 Mar-Apr;29(2):239-47. doi: 10.1016/j.biotechadv.2010.11.008. Epub 2010 Dec 10. Review.

PMID:
21146601
6.
7.

Challenges for the formulation of a universal vaccine against dengue.

Chokephaibulkit K, Perng GC.

Exp Biol Med (Maywood). 2013 May;238(5):566-78. doi: 10.1177/1535370212473703. Review.

PMID:
23856907
8.

Current status of flavivirus vaccines.

Barrett AD.

Ann N Y Acad Sci. 2001 Dec;951:262-71. Review.

PMID:
11797783
9.

New developments in flavivirus vaccines with special attention to yellow fever.

Pugachev KV, Guirakhoo F, Monath TP.

Curr Opin Infect Dis. 2005 Oct;18(5):387-94. Review.

PMID:
16148524
10.

Flaviviruses and flavivirus vaccines.

Heinz FX, Stiasny K.

Vaccine. 2012 Jun 19;30(29):4301-6. doi: 10.1016/j.vaccine.2011.09.114. Review.

PMID:
22682286
11.

Identifying protective dengue vaccines: guide to mastering an empirical process.

Halstead SB.

Vaccine. 2013 Sep 23;31(41):4501-7. doi: 10.1016/j.vaccine.2013.06.079. Epub 2013 Jul 26. Review.

12.

Rotavirus vaccines and vaccination in Latin America.

Linhares AC, Bresee JS.

Rev Panam Salud Publica. 2000 Nov;8(5):305-31. Review.

PMID:
11190969
13.

Attenuated D2 16681-PDK53 vaccine: defining humoral and cell-mediated immunity.

Rabablert J, Yoksan S.

Curr Pharm Des. 2009;15(11):1203-11. Review.

PMID:
19355961
14.

Dengue vaccine.

Simasathien S, Watanaveeradej V.

J Med Assoc Thai. 2005 Nov;88 Suppl 3:S363-77. Review.

PMID:
16858980
15.

Using recombinant DNA technology for the development of live-attenuated dengue vaccines.

Lee HC, Butler M, Wu SC.

Enzyme Microb Technol. 2012 Jul 15;51(2):67-72. doi: 10.1016/j.enzmictec.2012.05.005. Epub 2012 May 17. Review.

PMID:
22664189
16.
17.

Dengue vaccines for travelers.

Wilder-Smith A, Deen JL.

Expert Rev Vaccines. 2008 Jul;7(5):569-78. doi: 10.1586/14760584.7.5.569. Review.

PMID:
18564012
18.

Latest developments and future directions in dengue vaccines.

Thisyakorn U, Thisyakorn C.

Ther Adv Vaccines. 2014 Jan;2(1):3-9. doi: 10.1177/2051013613507862. Review.

19.

Vaccine-mediated immunity against dengue and the potential for long-term protection against disease.

Slifka MK.

Front Immunol. 2014 May 6;5:195. doi: 10.3389/fimmu.2014.00195. eCollection 2014. Review.

20.

New opportunities for control of dengue virus.

Roberts CH, Mongkolsapaya J, Screaton G.

Curr Opin Infect Dis. 2013 Dec;26(6):567-74. doi: 10.1097/QCO.0000000000000016. Review.

PMID:
24126721

Supplemental Content

Support Center